LPTX Live signals | Maximize Profits with Getagraph.com

SELL 100948 min ago

@ $3.52

Issued: 8 Feb 2024 @ 14:59

Return: -15.91%

Previous signal: Feb 7 - 15:44

Previous signal: Buy

Return: 2.03 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	100 726
Average Volume	325 474
Market Cap	75.79M
EPS	$0 ( 2024-03-22 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.740
ATR14	$0.0370 (1.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Mashiach Nissim	Buy	25 000	Stock Option (Right to Buy)
2024-01-29	Dietz Thomas John	Buy	30 000	Stock Option (Right to Buy)
2024-01-29	Schilsky Richard	Buy	25 000	Stock Option (Right to Buy)
2024-01-29	Granfield Christine	Buy	85 000	Employee Stock Option (Right to Buy)
2024-01-29	Baum Jason	Buy	85 000	Employee Stock Option (Right to Buy)

INSIDER POWER
66.56
Last 95 transactions
Buy: 11 050 606 \| Sell: 1 768 106

Volume Correlation

Long: 0.04 (neutral)

Short: -0.95 (very strong negative)

Signal:(47.698) Neutral

Leap Therapeutics Inc Correlation

10 Most Positive Correlations
LPCN	0.922
EWTX	0.919
CNDT	0.917
SRAX	0.915
CPIX	0.911
NESR	0.909
RPAY	0.905
VTRS	0.903
HNNA	0.9
SMSI	0.899

10 Most Negative Correlations
CNCE	-0.851
CNST	-0.84
TYHT	-0.838
UNCY	-0.828
ALR	-0.821
EPZM	-0.819
PSACU	-0.817
BTBD	-0.811
VERX	-0.81
DRNA	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Leap Therapeutics Inc Correlation - Currency/Commodity

0.60
( weak )

0.58
( weak )

0.00
( neutral )

0.48
( neutral )

-0.25
( neutral )

-0.32
( neutral )

Leap Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-427 000 (0.00 %)
EPS:	$-3.98

Q4	2023
Revenue:	$634 000
Gross Profit:	$524 000 (82.65 %)
EPS:	$-0.460

Q3	2023
Revenue:	$0
Gross Profit:	$-107 000 (0.00 %)
EPS:	$-0.510

Q2	2023
Revenue:	$0
Gross Profit:	$-106 000 (0.00 %)
EPS:	$-0.910

Financial Reports:

No articles found.

Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.